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Systematic review:Efficacy and safety ofmedical
marijuana in selected neurologic disorders
Report of the Guideline Development Subcommittee of the
American Academy of Neurology
ABSTRACT
Objective: To determine the efficacy of medical marijuana in several neurologic conditions.
Methods:We performed a systematic review ofmedical marijuana (1948–November 2013) to address
treatment of symptoms of multiple sclerosis (MS), epilepsy, and movement disorders. We graded the
studies according to the AmericanAcademy ofNeurology classification scheme for therapeutic articles.
Results: Thirty-four studies met inclusion criteria; 8 were rated as Class I.
Conclusions: The followingwere studied in patients withMS: (1) Spasticity: oral cannabis extract (OCE)
is effective, and nabiximols and tetrahydrocannabinol (THC) are probably effective, for reducing patient-
centered measures; it is possible both OCE and THC are effective for reducing both patient-centered
and objective measures at 1 year. (2) Central pain or painful spasms (including spasticity-related pain,
excluding neuropathic pain): OCE is effective; THC and nabiximols are probably effective. (3) Urinary
dysfunction: nabiximols is probably effective for reducing bladder voids/day; THCandOCE are probably
ineffective for reducing bladder complaints. (4) Tremor: THC and OCE are probably ineffective; nabixi-
mols is possibly ineffective. (5) Other neurologic conditions: OCE is probably ineffective for treating
levodopa-induceddyskinesias in patientswith Parkinson disease.Oral cannabinoids are of unknowneffi-
cacy in non–chorea-related symptoms of Huntington disease, Tourette syndrome, cervical dystonia, and
epilepsy. The risks and benefits of medical marijuana should be weighed carefully. Risk of serious
adverse psychopathologic effects was nearly 1%. Comparative effectiveness of medical marijuana
vs other therapies is unknown for these indications. Neurology® 2014;82:1556–1563
GLOSSARY
AAN5 American Academy of Neurology; AE5 adverse effect; CBD5 cannabidiol; CI5 confidence interval; CRS5 category
rating scale;HD5Huntington disease; ITT5 intention-to-treat;MS5multiple sclerosis;NRS5 numeric rating score;OCE5
oral cannabis extract; THC 5 D-9-tetrahydrocannabinol; UHDRS 5 Unified Huntington’s Disease Rating Scale; UPDRS 5
Unified Parkinson’s Disease Rating Scale; VAS 5 visual analog scale.
Marijuana contains approximately 60 pharmaco-
logically active compounds (“cannabinoids”).
D-9-Tetrahydrocannabinol (THC) was isolated
in 1964 and the nonpsychoactive cannabidiol
(CBD) in 1963; the ratio in botanical and phar-
maceutical preparations determines therapeutic vs
psychoactive effects, with the latter emerging when
THC is higher in concentration. The presence of can-
nabinoid receptors in the brain led to discovery of
endogenous ligands (endocannabinoids) such as
anandamide and 2-arachidonylglycerol. The endocan-
nabinoid system is widely distributed in the brain and
spinal cord,1,2 with CB-1 receptors concentrated in the
hippocampus, association cortices, basal ganglia, cerebel-
lum, spinal cord (especially dorsal root ganglia), and
peripheral nerves, including presynaptic sympathetic
nerve terminals (and are notably absent from thalamus
and brainstem). CB-2 receptors are found in the periph-
ery, including lymph tissue, and in lower concentrations
in some brain regions, including the periaqueductal gray.
Activation through G-coupled membrane proteins
causes physiologic responses expected from these regions,
including feelings of well-being or psychosis (depending
on the “dose” of THC), impaired memory and cognitive
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processing, slowed locomotor function, as well as antino-
ciceptive,3 antiemetic, antispasticity, and sleep-promoting
effects. Receptor activation inhibits adenylate cyclase,
converting cyclic adenosine monophosphate to aden-
osine triphosphate, and inhibits release of multiple
neurotransmitters, including acetylcholine, dopamine,
and glutamate, when neuronal excitation is present.4
Indirect effects on opiate, serotonin, NMDA, and
g-aminobutyric acid receptors allow endocannibinoids
to modulate other networks.3 The concentration of
THC present in formulations and the ratio of THC
to CBD, which limits THC’s psychoactive effects,
play a role in therapeutic effects of cannabis products.
Table 1 presents the cannabinoid formulations exam-
ined here. A variety of formulations was used, with
differing amounts of THC and CBD: some were
pills, one was a mucosal spray, and some were vapor-
ized or smoked.
This evidence-based systematic review seeks to
answer questions regarding safety and efficacy of can-
nabinoids in relieving/reducing the following:
1. Spasticity in patients with multiple sclerosis (MS)
2. Central pain and painful spasms in MS (pain
could be from any etiology, including spasticity,
but excluding neuropathic pain)
3. Bladder dysfunction in MS
4. Involuntary movements, including tremor, in
MS
5. Dyskinesias of Huntington disease (HD), levodopa-
induced dyskinesias of Parkinson disease, cervical dys-
tonia, and tics of Tourette syndrome
6. Seizure frequency in epilepsy
DESCRIPTION OF THE ANALYTIC PROCESS The
American Academy of Neurology (AAN) Guideline
Development Subcommittee convened an expert
panel to develop the systematic review (appendices
e-1 and e-2 on the Neurology® Web site at
Neurology.org). We searched Medline, EMBASE,
PsycINFO, Web of Science, and Scopus. Appendix
e-3 presents the original search strategy employed for
Medline (1948–January 2013) and updated strategies
for all databases searched. The search yielded 1,729
abstracts. We examined the listed conditions and
excluded non-neurologic pain (e.g., cancer, surgery-
related) as well as other non-neurologic conditions
(e.g., nausea). Surveys, case reports/series, and non–
placebo-controlled trials were excluded. Of the 1,729
abstracts reviewed, we reviewed the full text of 63
articles and found that 33 met inclusion criteria.
An updated search through November 2013 yielded
one article for inclusion. We classified these following
the AAN’s therapeutic scheme (appendix e-4). Some
articles were used to answer more than one question.
Unless otherwise stated, multiple outcomes were
corrected by the author panel with a Bonferroni
Table 1 Cannabinoid formulations
Generic name Trade name Manufacturer Dosage and components Study and dosage used of this formulation
Oral administration
Cannabis extract Cannador IKF, Berlin, Germany Ratio of D9-THC 2.5 mg:
CBD 1.25 mg
Mean 0.146 mg/kg/d up to maximum of 1.25 mg/kg/d (Carroll 200436);
mean 1.25 mg/kg/d up to maximum of 25 mg/d; maximum varied by
weight (Zajicek 20037)
Cannabis extract None Not stated Ratio of D9-THC 2.5 mg:
CBD 0.9 mg
Mean 0.146 mg/kg/d up to maximum of 0.25 mg/kg/d (Vaney 20045)
Cannabis extract None NIH, Bethesda, MD 100 mg CBD 100–300 mg/d (Cunha 1980e2)
Cannabis extract None NIH, Bethesda, MD 100 mg CBD 10 mg/kg/d (Consroe 1991,35 Curtis 200931)
Dronabinol Marinol Solvay Pharmaceuticals,
Marietta, GA
2.5 mg D9-THC Maximum of 10 mg/d (Svendsen 2004,25 Müller-Vahl 200340);
maximum of 25 mg/d (Freeman 2006,28 Zajicek 20037)
Nabilone Cesamet Meda Pharmaceuticals,
Somerset, NJ
100 mg CBD 100 mg (Curtis 200931); 0.03 mg/kg (Fox 200229)
Oromucosal spray
administration
Nabiximols Sativex GW Pharmaceuticals,
PLC, London, UK
Ratio of D9-THC 2.7 mg:
CBD 2.5 mg/spray
Mean 7.19 mg/d (Kavia 201026)
Nabiximols Sativex GW Pharmaceuticals,
PLC, London, UK
Ratio of D9-THC 2.7 mg:
CBD 2.5 mg/spray
Dosage varied by study; maximum 65 mg/d (Collin 201010); maximum
120 mg/d (Wade 20046)
Smoked (inhaled)
marijuana
Marijuana None Source not stated 4% THC 4 puffs (hits)/d (Corey-Bloom 201214); 3.5%THC (Abrams 2007e12);
3.5%–7% (Wilsey 2008e10); 1%–8% THC (Ellis 2009e13); 0%–9.4%
(Ware 2010e14)
Abbreviations: CBD5 cannabidiol, a major less-psychoactive resin extract constituent of the plantCannabis sativa L (marijuana); THC5 D-9-tetrahydrocannabinol,
the principal psychoactive agent.
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correction. Study data are presented in tables e-1
through e-5.
ANALYSIS OF EVIDENCE Question. Do cannabi-
noids relieve spasticity in patients with MS?
Analysis.We found 4Class I,5–8 4 Class II,9–12 and 9 Class
III13–21 studies addressing the issue of spasticity. Because
of the possible confusion of varying evidence for the
different agents, we present our analysis by type of can-
nabinoid studied.
Nabiximols.AClass I multicenter study of 160 patients
compared self-titrated nabiximols with placebo for treat-
ing the most troublesome symptom measured by a 100-
point visual analog scale (VAS).6 No significant change
from baseline was seen at 6 weeks (difference 25.93;
95% confidence interval [CI] 213.52 to 1.65; p 5
0.124). Among patients reporting spasticity as the worst
symptom (n 5 37), there was a significant reduction in
VAS rating (mean reduction 31.2 in treated vs 8.4 in
placebo [p , 0.001, post–Bonferroni correction, 95%
CI 210 to 235]).
There were 3 Class II prospective studies. Amulticen-
ter investigation studied 189 subjects with definite MS
and spasticity; 124 received nabiximols and 65 received
placebo.9 The primary endpoint was a change in a
patient-recorded numeric rating score (NRS) (0–11
points).9 The intention-to-treat (ITT) population (n 5
184) analysis showed a 0.52-point treatment difference
favoring nabiximols (p 5 0.048; 95% CI 21.029 to
0.004 points).
One Class II multicenter study randomized 337 sub-
jects to receive nabiximols or placebo.10 The primary out-
come was the change from baseline in mean NRS (0–10)
assessed at treatment weeks 2, 6, 10, and 14. Clinically
meaningful improvement was defined as $30%
improvement on the NRS. In the ITT analysis, the treat-
ment difference of 0.23 was nonsignificant (p5 0.219).
Secondary endpoints were not significantly improved.
Another Class II study randomized 36 patients
receiving nabiximols for at least 12 weeks for spastic-
ity relief.12 The hazard ratio for treatment failure was
0.335 (95% CI 0.162–0.691) favoring treatment.
A Class III trial did not demonstrate efficacy.13
Another Class III trial did not perform statistics on the
data. After Bonferroni correction, there were no signifi-
cant differences on post hoc statistics.21
Oral cannabis extract and THC.We found 3Class I stud-
ies.5,7,8 In one study,5 patients received either escalating
doses of an oral cannabis extract (OCE) containing
THC and CBD for 14 days followed by placebo, or
placebo for 7 days and then treatment for 14 days. No
significant difference was seen for the primary outcome
measure, the Ashworth Spasticity Scale, in the 50 pa-
tients designated for ITT. Among 37 patients who
received at least 90% of their prescribed dose, active
treatment was associated with greater improvement in
the secondary outcome of spasm frequency (p5 0.013),
without improvement on the Ashworth scale. Because of
the small number of patients included, this study lacked
statistical precision to detect differences.
In a second Class I study, 277 patients with “stable
MS” and “muscle stiffness for at least 3 months” received
either cannabis extracts containing THC and CBD
(titrated to maximum daily dose of 25 mg THC) or
placebo.8 A 2-week titration was followed by 10 weeks
of maintenance, with assessments at 2, 4, 8, and 12
weeks. The primary endpoint was an 11-point category
rating scale (CRS) (0 5 very much better, 5 5 no dif-
ference, and 105 very much worse). The CRS is similar
to the NRS used in other studies. Relief of muscle stiff-
ness was equated with categories 0–3, with an odds ratio
(OR) of 2.26 for improvement at 12 weeks (95% CI
1.24–4.13; p 5 0.004).
In a third Class I study, 630 patients with MS-
related spasticity received THC or a combination
of THC and CBD, or placebo for each, titrated over
5 weeks and maintained for 8 weeks.7 There was no
significant treatment effect on the primary endpoint
of Ashworth scale for THC (mean change 1.86 vs
placebo 0.92, 95% CI 7 to 95; p5 0.94) or THC1
CBD (mean change 1.24 vs 0.92, 95% CI 6 to 60;
p 5 0.32). However, a beneficial effect was seen for
both active treatments on secondary outcomes of
patient-reported spasticity and pain (p 5 0.003).
A 12-month continuation study, rated Class II
because of loss at follow-up,11 found a mean
improvement in Ashworth score from study begin-
ning to study end of 1.82 (from baseline mean 22)
in patients treated with THC (computed 95% CI
0.54 to 3.1), 0.10 in the patients treated with THC/
CBD extract (computed 95% CI 20.98 to 1.18),
and 20.2 in the placebo group (p 5 0.01 adjusted
for ambulatory status and center, adjustment for
center because of center size).
Five Class III studies of oral cannabinoids showed
inconsistent results.16–20
Smoked marijuana. One Class III trial demonstrated a
mean decrease in modified Ashworth score in 30 subjects
who completed the trial (2.95 in treated subjects, 0.21 in
placebo; 95% CI 2.20–3.14; p , 0.001).14 A Class III
double-blind trial of 20 subjects, each of whom smoked
a single marijuana cigarette, found worsened posture and
balance after 10 minutes (p 5 0.018 post–Bonferroni
correction).15
Conclusions. For patients with spasticity:
OCE is established as effective for reducing
patient-reported scores (2 Class I studies7,8). OCE is
probably ineffective for reducing objective measures
at 12–15 weeks (1 Class I study7) but possibly effec-
tive at 1 year (1 Class II study11).
THC is probably effective for reducing patient-
reported scores (1 Class I study7). THC is probably
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ineffective for reducing objective measures at 15
weeks (1 Class I study7) but possibly effective at 1 year
(1 Class II study11).
Nabiximols is probably effective for reducing
patient-reported symptoms at 6 weeks (1 Class I study6)
and probably ineffective for reducing objective measures
at 6 weeks (1 Class I study6).
Smoked marijuana is of uncertain efficacy (insuffi-
cient evidence).
Clinical context. Standard medical therapy was contin-
ued in these studies, so no comment can be made as
to comparative effectiveness.
Multiple methods of measuring spasticity exist. A
recent study used correlations with changes on a standard
Patient Global Impression of Change scale22 to deter-
mine that a;30% change in spasticity, as measured by
the patient-reported NRS, best represented a clinically
important difference.23More improvements were seen in
subjective measures than objective measures, possibly
explained in part by the overall improvements in “feel-
ings” or well-being provided by marijuana, or by pain
relief allowing improved mobility.
Question. What is the efficacy of using cannabinoids
to treat central pain or painful spasms in MS?
Analysis. There were 5 Class I,5–8,24 2 Class II,10,11 and
6 Class III13,15,18–20,25 studies of cannabinoids for
treating central pain or spasms.
Nabiximols. A Class I study involved 66 patients with
neuropathic and central pain. Patients with only spastic-
ity or painless spasms were excluded.24 Patients were ran-
domized to nabiximols or placebo, and they rated their
pain on an 11-point NRS. During the study’s fourth
week, nabiximols was superior to placebo in reducing
pain intensity (treated: 41% decrease, placebo: 22%
decrease) and in decreasing both the mean pain intensity
of22.7 (95% CI 3.4–2.0, placebo21.4, 95% CI 2.0–
0.8; p 5 0.005) and pain-related sleep disturbances.
In a Class II study of 337 patients, 167 receiving na-
biximols and 170 placebo, no significant difference was
seen in the secondary outcomes of change in spasm fre-
quency (treated: 20.86, placebo: 20.85; p 5 0.955)
and pain NRS (treated: 21.22, placebo: 21.14;
p 5 0.763).10 A Class III study did not show a signif-
icant effect of nabiximols on mean pain VAS score over
6 weeks.13
OCE and THC. In a previously described Class I study,7
pain reduction after 14 weeks of treatment was described
by 50% of those receiving THC, 46% of those receiving
THC/CBD, and 30% of those receiving placebo. These
differences were significant after Bonferroni correction
(p 5 0.022 for THC, p 5 0.033 for THC/CBD).
The Class II continuation study included 356 patients
reporting pain and 438 reporting muscle spasms.11 Pain
improvement was reported in 28% receiving THC,
31% receiving THC/CBD, and 23% receiving placebo
(p 5 0.002). Muscle spasm reduction was reported
in 29% of those receiving THC, 36% receiving
THC/CBD, and 23% receiving placebo (p 5 0.002).
Another Class I study,8 described previously, which
included pain and spasms as a secondary outcome, found
that the proportion of patients with self-reported relief
(0–3 on CRS) was greater in the cannabis group than in
the placebo group at all visits (p , 0.025).
In a Class I study described previously,6 at 6 weeks no
significant difference in ratings was seen for pain or
spasms between the 2 groups (pain: n 5 36, 18.73,
95% CI 210.39 to 27.84; spasms: n 5 38, difference
25.3, 95% CI 219.81 to 9.22). Because of the large
placebo response to pain, this part of the study could not
be interpreted.
In a Class I randomized, placebo-controlled, cross-
over study, 50 patients with MS were treated for 14 days
with THC/CBD capsules, which decreased spasm
frequency from 1.0 to 0.7/day (treated) relative to
0.9–0.8/day (placebo) (95% CI of the difference
between periods of placebo and cannabis: 0.99–3.19;
p 5 0.058).5 The study had limited power to detect
differences.
Four Class III studies found varying results after
Bonferroni correction.18–20,25
Smoked marijuana. There were 2 Class III studies.14,15
In a crossover study of smoked marijuana, 30 patients
with MS and spasticity showed smoking marijuana sig-
nificantly reduced pain: decrease to 8.27 from 16.61
in patients receiving treatment vs 11.52 from 14.51
in patients receiving placebo (95% CI 2.48–10.01;
p 5 0.008).14
A study of dynamic posturography among 10
adult patients with spasticity and 10 matched normal
volunteers found smoking marijuana impairs posture
and balance in patients with spasticity.15
Conclusion. For patients with MS with central pain or
painful spasms, OCE is effective for reduction of central
pain (2 Class I studies7,8). THC or nabiximols (1 Class I
study each7,24) are probably effective for treating MS-
related pain or painful spasms. Smoked marijuana is of
unclear efficacy for reducing pain (2 Class III studies that
examined different issues14,15).
Question. Do cannabinoids help treat bladder dys-
function in MS?
Analysis. Nabiximols. A Class I study of 135 patients with
MS and detrusor overactivity showed no difference in
mean daily episodes of incontinence (21.08 using na-
biximols spray relative to20.98 placebo; p5 0.056).26
After Bonferroni correction, the significant secondary
outcomes were the Overall Bladder Condition rating
scale score20 (p 5 0.008), the patients’ Global Impres-
sion of Change score27 (p5 0.04), and number of voids
per 24 hours (p5 0.008). Another Class I study, which
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looked at bladder complaints as a secondary outcome,
did not show improvement.6
Oral cannabinoids and THC.One Class I study exam-
ined bladder complaints as a secondary outcome, and
no improvement was noted with either THC or
OCE.7 Another Class I study, which examined blad-
der complaints over time, also noted no improvement
of self-reported bladder complaints.5
A Class II substudy (255 of the original 630 patients)
of the Cannabinoids inMS studymeasured incontinence
episodes.28 Fewer than half the patients were analyzed,
and thus the results cannot inform reliable conclusions.
Conclusion.Nabiximols is probably effective for reducing
the number of bladder voids per day at 10 weeks (1 Class
I study26). THC and OCE are probably ineffective for
reducing bladder complaints (1 Class I study7). Nabix-
imols is of unknown efficacy in reducing overall bladder
symptoms (contradictory Class I studies).
Question. Do cannabinoids help treat tremor in MS?
Analysis. Tremor was included as a secondary out-
come in 3 Class I studies,5–7 1 Class II study,10 and
2 Class III studies.29,30
Nabiximols. In a Class I study, the oral spray na-
biximols produced no change in VAS report of
tremor in 13 patients (221.42 treated vs 225.17
placebo, p 5 0.810).6 Because of the small number
of patients included, the study was underpowered to
detect differences.
In a Class II study of 337 patients, an unspecified
number of whom rated tremor on NRS, no response
was reported with nabiximols as compared with pla-
cebo (20.56 vs 20.31, p 5 0.255).10
Oral cannabinoids and THC. In a Class I study of 630
patients, tremor was listed as a symptom in diaries kept
by 391 patients receiving capsules of THC, THC/CBD,
or placebo.7 Neither self-report (p 5 0.398) nor physi-
cian assessment (p 5 0.052) noted a response.
In the subset of 26 patients reporting tremor in a
third Class I study of 50 patients, no response to
CBD was observed by patient report (p 5 0.9) or
physician report (p 5 0.82).5 This study had limited
power to detect differences.
Two Class III studies examined tremor; no improve-
ment was seen with oral nabilone29 or THC/CBD.30
Conclusions. THC and OCE are probably ineffective
for treating MS-related tremor (1 Class I study7).
Nabiximols is possibly ineffective (1 Class II study10).
Question. Do cannabinoids reduce symptoms in
involuntary movement disorders?
Analysis. Huntington disease. A Class I crossover study
evaluated nabilone for symptomatic HD treatment
(n 5 37, two 5-week treatment periods separated by
a 5-week washout period).31 There was no significant
difference on the primary outcome of Unified Hun-
tington’s Disease Rating Scale (UHDRS)32 total motor
score (treatment difference 0.86, 95% CI21.8 to 3.52;
p5 0.5), with a 1-point change in UHDRS likely to be
clinically significant.33 This study was underpowered to
detect anything but a large difference.
A 2012 AAN guideline specifically examined the
efficacy of marijuana for treating chorea in HD.34
In another Class III crossover study (15 patients), the
efficacy of CBD capsules (10 mg/kg/d in 2 divided
doses) was evaluated for symptomatic HD treatment.35
This study was underpowered to detect differences.
Conclusion. Whereas these 2 studies31,35 suggest lack
of benefit, both were underpowered to detect differ-
ences, and thus no reliable conclusions can be drawn.
Levodopa-induced dyskinesias in Parkinson disease.A Class I
double-blind crossover study examined the effectiveness
of CBD extract in 1.25- or 2.5-mg capsules with an aver-
age daily dose of 0.146 mg/kg/d in the treatment of
levodopa-induced dyskinesias in 19 patients.36 The pri-
mary outcome was score on Part IV (dyskinesia section,
items 32–34) of the Unified Parkinson’s Disease Rating
Scale (UPDRS).37 The overall treatment effect was
10.52 on items 32–34 of the UPDRS, which indicated
a worsening but was nonsignificant (p 5 0.09). No sec-
ondary outcomes were affected by treatment. A Class III
study examined dopamine-induced dyskinesias and
showed improvement in 7 patients.38
Conclusion. OCE is probably ineffective for treating
levodopa-induced dyskinesias in patients with Parkin-
son disease (1 Class I study36).
Tourette syndrome. A Class II study examined 9 meas-
ures in 12 patients in a placebo-controlled, crossover
study, using a single-dose THC capsule (5.0, 7.5, or
10.0 mg).39 Because of the small number of patients
and the large number of items tested, this trial lacks sta-
tistical power to enable reliable conclusions to be drawn.
In a Class III placebo-controlled study of tics in 24
patients, patients received up to 10 mg/d of THC
orally over 6 weeks.40 After Bonferroni correction,
there were no significant differences.
Conclusion. For patients with Tourette syndrome,
data are insufficient to support or refute efficacy of
THC for reducing tic severity (1 Class II study, 1 Class
III study).39,40
Cervical dystonia.One Class III study examined the
effect of dronabinol on cervical dystonia.e1 No differ-
ences were detected in any outcome measure, but the
study was underpowered to detect differences.
Conclusion. For patients with cervical dystonia, data
are insufficient to support or refute the efficacy of
dronabinol.
Question.Do cannabinoids decrease seizure frequency
in epilepsy?
Analysis. There were no Class I–III studies. There
were 2 Class IV studies that did not demonstrate a
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significant benefit and did not show adverse effects
(AEs) over 3–18 weeks of treatment.e2,e3
Conclusion. For patients with epilepsy, data are insuffi-
cient to support or refute the efficacy of cannabinoids
for reducing seizure frequency (no Class I–III studies).
Clinical context. Neither the present review, nor a
Cochrane review, which includes abstracts, non–peer-
reviewed literature, and anecdotal reports of smoked
cannabis use by patients with seizure disorders,e4 con-
cluded there is sufficient evidence to prescribe CBDs or
recommend self-treatment with smoked marijuana.
ADVERSE EFFECTS In looking at marijuana-
related AEs, we excluded studies that reanalyzed
earlier studies, used a single dose of medication, or
had Class IV evidence or unclear information about
AEs.15,17,28,38,e2,e3 See table e-6 for details.
Overall, 1,619 patients were treated with cannabi-
noids for less than 6 months. Meta-analysis of simple
proportions yielded 6.9% (95% CI 5.7%–8.2%) who
stopped the medication because of AEs. Of the 1,118
who received placebo, 2.2% (95% CI 1.6%–3.5%)
stopped because of AEs. Data on the symptoms that
caused medication withdrawal were often incomplete.
Among patients treated with cannabinoids, the follow-
ing symptoms appeared in at least 2 studies: nausea,
increased weakness, behavioral or mood changes (or
both), suicidal ideation or hallucinations (or both), diz-
ziness or vasovagal symptoms (or both), fatigue, feelings
of intoxication. Psychosis, dysphoria, and anxiety are
associated with higher concentrations of THC, which
are not typical of the studies we analyzed. There was one
death “possibly related” to treatment (a seizure, followed
by fatal aspiration pneumonia).18
A single Class II study looked at the effects of canna-
binoids at 1 year. Thirty-one of 207 patients treated with
cannabis extract (15%) stopped medication, as did 28 of
197 treated with THC (14%) and 10 of 207 given pla-
cebo (5%).11 However, AEs were not necessarily the
reason medication was stopped. For example, cannabi-
noids inhibit many enzymes of the cytochrome P-450
system, which will cause interactions with other medica-
tions being taken, especially opiates for pain. No direct
fatalities (overdoses) have been attributed to marijuana,
even in recreational users of increasingly potent mari-
juana, possibly because of the lack of endocannabinoid
receptors in the brainstem. Clearly, deleterious effects on
judgment can indirectly endanger patients who perform
dangerous tasks such as driving. In addition, smoking
and possibly even use of vaporized preparations expose
users to carbon monoxide and other respiratory toxins.
Clinical context. AEs are a significant concern with
marijuana use. Outside the setting of treatment trials,
cognitive impairment is more likely to be of concern.
One study of patients with MS who smoked cannabis
at least once a month showed an increase in cognitive
impairment.e5 Another article showed that patients with
MS who used cannabis were twice as likely to be clas-
sified as globally cognitively impaired as those who did
not use cannabis.e6 Some patients who have neurologic
conditions may have preexisting cognitive dysfunction,
which may increase their susceptibility to cannabinoids’
toxicities.e5,e6 Moreover, it is especially concerning that a
medication that may have an AE of suicide may be
prescribed in a population such as patients with MS
who already are at increased suicide risk.e7
RECOMMENDATIONS FOR FUTURE RESEARCH
Placebo effect, which has been reported to be as high
as 70%,35 interferes with proof of efficacy, although
the ability to recognize treatment was mitigated by
preparations with less THC and thus less psychoac-
tive effects. Although masking may be lost due to the
non-naive subject’s recognition of his or her assigned
group (treatment vs control),2,3,e8,e9 interviews of
subjects also found many who guessed incorrectly
which group they were in, especially the first time
cannabis was used.e10
Recruitment into studies of a drug currently classi-
fied as Schedule I in the United States may be difficult
due to the stigma attached or the additional burden
placed on researchers, although in British studies the
prohibition from driving for the duration of the study
was more likely to dissuade patients from enrolling.
The many formulations and doses we studied
make comparative analysis of cannabinoid efficacy
difficult. Cannabis smoked in cigarettes or pipes,
the most familiar form of cannabis, was the least stud-
ied outside of user surveys, which often are generated
by anonymous questionnaires, sources from which
detailed information is difficult to obtain. Even in
surveys of identifiable subjects, such as those derived
from support groups, reliability suffers.e11
In addition, the need to use many subjective meas-
ures such as patient-driven symptom rating scales, espe-
cially of pain, is a fundamental problem in this field.7,8,e10,
e12–e14 Even “objective” measures such as walking times
and the Ashworth Spasticity Scale have poor reliability,e15
as they will be influenced by patient’s improved pain
control or general improvement in well-being. Despite
this, from a patient’s perspective insights gained from
subjective outcomes are probably even more important
than objective outcomes.
Future research with randomized controlled studies
is necessary in order to determine the efficacy of this
medication class. The present review downgraded some
studies for inadequate outcome concealment and com-
parison of baseline characteristics. Some studies were
underpowered to detect differences; others had too
many dropouts for reliable conclusions to be drawn.
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Other questions concerning the anti-inflammatory and
immunologic effects of cannabinols evolved from the
presence of CB-2 receptors in the lymphatic system
and observation of neuroprotective effects in animal
models of diseases such as amyotrophic lateral sclerosis.4
Disease-modifying effects in MS were not confirmed in
a recent clinical study.e16
Cannabinoids should be studied as other drugs
are, to determine their efficacy, and when evidence
is available, should be prescribed as other drugs are.
Twenty states and the District of Columbia have
legalized the medical use of marijuana, and 2 have de-
criminalized all use. This should encourage research-
ers to continue seeking answers to the benefits of
marijuana use in patients who have neurologic illness.
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